Keyphrases
Verteporfin
100%
Bionic Eye
100%
Wet Age-related Macular Degeneration
75%
Penetratin
75%
Neovascular
75%
Laser-induced
75%
Low-density Lipoprotein
50%
Non-invasive Strategies
25%
Immunogenic
25%
Myopic Choroidal Neovascularization (mCNV)
25%
Vascular Endothelial Growth Factor Inhibitors
25%
Membrane-active Peptides
25%
Eye Injuries
25%
Nano Eye-drops
25%
Visual Therapy
25%
Secondary Eyes
25%
Intercellular Adhesion molecule-1 (ICAM-1)
25%
PDT Treatment
25%
Blood-retinal Barrier
25%
Recognizability
25%
Photodynamic
25%
Intravitreal
25%
Low-density Lipoprotein Receptor
25%
Local Therapy
25%
Carboxyfluorescein
25%
Pharmacology, Toxicology and Pharmaceutical Science
Age Related Macular Degeneration
100%
Verteporfin
100%
Nicotinic Acid
100%
Neovascularization (Pathology)
100%
Penetratin
75%
Low Density Lipoprotein
50%
Vasculotropin Inhibitor
25%
Eye Injury
25%
Lipoprotein A
25%
Vasculotropin
25%
Intercellular Adhesion Molecule 1
25%
6 Carboxyfluorescein
25%
Low Density Lipoprotein Receptor
25%
Subretinal Neovascularization
25%
Medicine and Dentistry
Verteporfin
100%
Age Related Macular Degeneration
100%
Penetratin
75%
Low-Density Lipoprotein
50%
Nanoparticle
25%
Single Drug Dose
25%
6 Carboxyfluorescein
25%
Intercellular Adhesion Molecule 1
25%
Choroidal Neovascularization
25%
Niacin
25%
LDL Receptor
25%
Eye Injury
25%
Local Therapy
25%
Vasculotropin
25%
Blood-Retinal Barrier
25%
Vasculotropin Inhibitor
25%